Why Is CLIMB BIO INC (CLYM) Stock Down Today?

Why CLYM stock is down today

Climb Bio Inc (CLYM) shares fell 6.58% to $14.06 in early trading on Tuesday. The decline followed a sharp intraday reversal after the stock opened with a modest -0.9% gap and briefly surged to a session high of $17.93. The pullback came despite the release of positive Phase 1 trial data for CLYM116, the company’s drug candidate for IgA nephropathy.

What Happened

Climb Bio announced initial data from its Phase 1 trial of CLYM116, showing a 29-day half-life and near-complete suppression of APRIL, a protein linked to IgA nephropathy. The drug also demonstrated 60-75% suppression of IgA/Gd-IgA1 levels through 12 weeks. The company said the results support a dosing interval of every 12 weeks and that the drug was generally well-tolerated. These findings were disclosed in a Form 8-K filed with the SEC on September 3. The company also announced plans to present at investor conferences on September 9 and 16.

Despite the positive data, the stock reversed from its early high, closing the session near $14.06. The mixed reaction may reflect investor caution ahead of Phase 2 data expected in the first half of 2027. Analysts from HC Wainwright, Wedbush, and Truist have all maintained or raised price targets in recent weeks, suggesting continued optimism about the drug’s potential.

What The Data Shows

The stock opened at $14.92 and reached a high of $17.93 before falling to a session low of $13.50. Volume stood at 1.5 million shares, or 1.2 times the 3-month average. The stock has traded between $1.54 and $18.33 over the past 52 weeks. On Tuesday, it also printed a fresh 52-week low. Recent insider activity includes a $407,000 sale by CEO Brennan Aoife on June 29.

What To Watch

Investors should watch for the company’s Phase 2 IgA nephropathy data, expected in the first half of 2027. Coverage breadth and analyst reactions to that data will be key indicators for future stock performance.